Sanara MedTech (SMTI)
Makes surgical repair products for soft tissue and bone fusion.
Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates
Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.23 per share a year ago.
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the second quarter ended June 30, 2026.
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this c.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)
NEW YORK, July 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sanara MedTech Inc. (NASDAQ: SMTI ) related to its sale to MiMedx Group, Inc. Under the terms of the proposed transaction, Sanara shareholders are expected to receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara common stock.
Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders PR Newswi
Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Sanara (Nasdaq: SMTI) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with MiMedx. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Sanara MedTech Inc. (NASDAQ: SMTI) to MiMedx Group, Inc. for $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara common stock. Halper Sadeh encourages Sanara shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The inves.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sanara MedTech: From Cash Burner To Profitable Growth
Sanara MedTech delivered a strong Q1 2026, with 19% revenue growth, 93%+ gross margins, and its first GAAP profit in years. SMTI's strategic discontinuation of the THP segment has materially improved profitability, allowing management to focus on the high-return Surgical business. Operating margins now exceed 10%, and guidance for 2026 revenue is $116M–$121M, supporting a Buy rating despite the recent 30% stock rally.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter
SMTI Investors Have Opportunity to Join Sanara MedTech Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanara MedTech Inc. ("Sanara" or "the Company") (NASDAQ: SMTI) for violations of the securities laws.
SMTI Investors Have Opportunity to Join Sanara MedTech Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanara MedTech Inc. (“Sanara” or “the Company”) (NASDAQ: SMTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open.
Sanara MedTech, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sanara MedTech, Inc. , (“ Sanara " or the "Company") ( NASDAQ : SMTI ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.